efaroxan has been researched along with Compensatory Hyperinsulinemia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antoine, MH; Aynsley-Green, A; Barnes, PD; Clayton, P; Cosgrove, KE; De Lonlay, P; de Tullio, P; Dunne, MJ; Hussain, K; Lebrun, P; Lee, AT; Lindley, KJ; McCloy, R; Nihoul-Fékété, C; Pirotte, B; Rahier, J; Robert, JJ; Saudubray, JM | 1 |
1 other study(ies) available for efaroxan and Compensatory Hyperinsulinemia
| Article | Year |
|---|---|
BPDZ 154 activates adenosine 5'-triphosphate-sensitive potassium channels: in vitro studies using rodent insulin-secreting cells and islets isolated from patients with hyperinsulinism.
Topics: Adenosine Triphosphate; Adolescent; Adrenergic alpha-Antagonists; Animals; Benzofurans; Benzothiadiazines; Calcium Radioisotopes; Cell Line; Child, Preschool; Cyclic S-Oxides; Female; Glucose; Humans; Hyperinsulinism; Hypoglycemic Agents; Imidazoles; Infant; Insulin; Insulin Secretion; Insulinoma; Islets of Langerhans; Male; Pancreatic Neoplasms; Potassium Channels; Rats; Rats, Wistar; Rubidium Radioisotopes; Tolbutamide | 2002 |